Leicester Precision Medicine Institute Martin Tobin Director Leicester

Leicester Precision Medicine Institute Martin Tobin Director, Leicester Precision Medicine Institute martin. tobin@leicester. ac. uk

Capacity, Resource and Investment Life Sciences Innovation Basic Research Target Validation Po. C Industry/NHS/University Collaboration: Reduce the Peaks and fill the Gap Valley of Death Medical Development Efficacy Evaluation TRL 1 Dale of Despair Clinical Practice & Adoption TRL 10 Translational Requirements from Concept to Commercialisation Improved Validation Improved Evidence Improved Implementation

Precision Medicine • provide early, accurate diagnosis and identify the best treatment and disease management, tailored for individual patients – replaces a one-size-fits-all approach to medicine • genomics, detailed biochemical measures, digital monitoring and imaging enable us to measure more aspects of our health than ever before. • with electronic healthcare records, these provide information on a scale previously unavailable to predict, diagnose and treat disease.

Leicester Precision Medicine Institute Leading academic discoveries Hospital Trust Industry collaboration Population Discovery Evaluation Implementation

Leicester Precision Medicine Institute • LPMI unites the research missions of both: University of Leicester and University Hospitals Leicester NHS Trust: – To drive precision medicine research alongside clinical practice – To adopt precision medicine and healthcare innovations for • more effective & safer healthcare to our population • for more efficient use of NHS resources – To train, recruit and retain the best clinicians and academics – To be partner of choice for academic and industrial collaboration A Precision Medicine Accelerator from Discovery to Implementation Discovery Evaluation Implementation

Strategy Sustainable growth in: • Respiratory • Oncology • Cardiovascular • Diabetes/Lifestyle and Exercise BRC ECMC CTUs EMBER Develop capability in: • Ethnic Health Research • Microbial disease, including TB • Acute Care & Emergency Medicine – Med Tech platform – NIHR Clinical Research Facility • Renal disease inter-disciplinary research, cross-cutting expertise and technology Genomics & Phenomics Analytics, Informatics Drug and diagnostic discovery Environmental impact

Clinical population and Single Acute Trust • Leicester is most ethnically diverse city in Britain • 52% BME Patient & Public Involvement • Highest proportion of South Asians: • India, Pakistan, Bangladesh, Sri Lanka • Distinct disease characteristics • Type II diabetes, coronary artery disease • Static population under single large acute NHS Trust • East Midlands Centre for Ethnic Health • General Practice links and studies Patient Education

Sampling and Measurement of the breath-ome • Standardised and reproducible breath sampling • State of the art analytical tools – Provides detailed chemical fingerprinting of the breath volatiles • Bringing together multiple disciplines – Science, Engineering Space and Medicine to deliver true innovation • Working with industry

Studying populations at scale EXCEED (10, 000) COPD Asthma Gen. Vasc (23, 000) Coronary disease Clinical Trials Unit Genomics England GRAPHIC (2, 200) Renal disease NIHR Clinical Research Facility International genomics consortia Testbeds: pharmacogenetics UK Biobank

Leicester Precision Medicine Institute Translational Expertise Diagnostics Med-Tech Drug Discovery Cancer Centre A&E Medicine Respiratory Genomics Van Geest Biomarker Centre NIHR BRC Molecular Diagnostics Facility Chemical Pathology NCAT Diabetes and Lifestyle Cardiovascular Clinical Diagnosis Clinical Therapy Patient Access Sample access Clinical Trials Imaging Health Informatics Big Data Microbial Research Renal Disease Molecular Diagnostic

Leicester Precision Medicine Institute Translational Strengths Discover causes & biomarkers Proof of principle Lab validation Research: Cancer Infection, immunity and Immunology Cardiovascular Neuropsychiatry Health Sciences Genetics Drug Discovery & Diagnostics Centre (LD 3) Clinical validation Clinical utility NIHR BRC & CRF Cardiovascular, Respiratory Lifestyle (Diabetes) Cancer Research ECMC LLIPS, CLAHRC Market approval Market uptake East Midlands Academic Health Science Network (AHSN) UHL trust 3 x. CCG Clinical Trials Unit Renal Clinical Research Group MRC Pathology NODE EMBER Preclinical Research facility Electronic Health Records: Bioinformatics BINERI Patient Safety Assess Needs Discover Evaluate Implement